Hwaseong, South Korea
Hwaseong, South Korea

Time filter

Source Type

Patent
JW Pharmaceutical Corporation | Date: 2015-04-15

This invention relates to a novel doripenem crystal, a solvate thereof, and a preparation method thereof and, more specifically, to a novel doripenem anhydride crystal, a method of preparing the doripenem anhydride crystal using various solvents, and a solvate of doripenem.


Patent
Bio Synectics Inc. and JW Pharmaceutical Corporation | Date: 2010-09-20

The present invention relates to a nanoparticle of oxaliplatin, which is a water-soluble active substance, a pharmaceutical composition containing the same, and a method for preparing an orally administrable oxaliplatin nanoparticle by emulsifying a lipid mixture solution wherein a solid lipid and a surfactant are mixed in an aqueous mixture solution wherein oxaliplatin and a specific cosolvent are mixed and then removing the solid lipid and the cosolvent using a supercritical fluid gas. By providing oxaliplatin, which is currently available only in injection form for parenteral administration, in the form of a nanoparticle, the present invention allows for the development of orally administrable oxaliplatin which is stable against gastric acid and has improved bioavailability, thereby improving patient compliance through avoiding the inconvenience of injection and greatly reducing medical cost. Since the oxaliplatin nanoparticle can be prepared economically using a relatively inexpensive supercritical fluid producing facility, it can be prepared via a simple process with high yield in commercial scale.


Patent
JW Pharmaceutical Corporation and Bio Synectics Inc | Date: 2012-08-01

The present invention relates to a nanoparticle of oxaliplatin, which is a water-soluble active substance, a pharmaceutical composition containing the same, and a method for preparing an orally administrable oxaliplatin nanoparticle by emulsifying a lipid mixture solution wherein a solid lipid and a surfactant are mixed in an aqueous mixture solution wherein oxaliplatin and a specific cosolvent are mixed and then removing the solid lipid and the cosolvent using a supercritical fluid gas. By providing oxaliplatin, which is currently available only in injection form for parenteral administration, in the form of a nanoparticle, the present invention allows for the development of orally administrable oxaliplatin which is stable against gastric acid and has improved bioavailability, thereby improving patient compliance through avoiding the inconvenience of injection and greatly reducing medical cost. Since the oxaliplatin nanoparticle can be prepared economically using a relatively inexpensive supercritical fluid producing facility, it can be prepared via a simple process with high yield in commercial scale.


Patent
Jw Pharmaceutical Corporation | Date: 2011-10-14

This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method of preparing the same, and the use thereof to treat diseases such as cancer, in particular, acute myeloid leukemia.


Patent
Jw Pharmaceutical Corporation | Date: 2012-08-24

Disclosed is a composition including a pyrazino-triazine derivative and a pharmaceutically acceptable salt thereof. The composition includes a solubilizer or a stabilizer and thus can exhibit very excellent solubility and stability.


Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating NSCLC.


Patent
JW Pharmaceutical Corporation | Date: 2013-08-21

This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method ofpreparing the same, and the use thereofto treat diseases such as cancer, in particular, acute myeloid leukemia.


Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating NSCLC.


Disclosed is an interferon- (IFN-) fused protein having IFN- fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.


News Article | November 15, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “JW Pharmaceutical Corporation – Product Pipeline Review – 2016” new report to its research database. The report spread across 39 pages with table and figures in it. The report JW Pharmaceutical Corporation - Product Pipeline Review - 2016, provides an overview of the JW Pharmaceutical Corporation’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by JW Pharmaceutical Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/jw-pharmaceutical-corporation-product-pipeline-review-2016/ Scope - The report provides a snapshot of the pipeline therapeutic landscape of JW Pharmaceutical Corporation - The report provides overview of JW Pharmaceutical Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses JW Pharmaceutical Corporations pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features JW Pharmaceutical Corporations out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate JW Pharmaceutical Corporations strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for JW Pharmaceutical Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding JW Pharmaceutical Corporations pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150

Loading JW Pharmaceutical Corporation collaborators
Loading JW Pharmaceutical Corporation collaborators